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In the last two decades, mortality from primary liver cancer has increased in the UK. We aimed to determine whether the incidence
trends for these cancers were similar and in particular if the increasing occurrence of cholangiocarcinoma has continued. We
calculated directly age-standardised incidence rates (using the European standard population) by subsite and histological type for all
cancers of the liver, gallbladder and biliary tract in England and Wales from 1971 to 2001, using cancer registry data. The incidence of
cancers of the liver, gallbladder and biliary tract increased, with the greatest rise, around 12-fold, in intrahepatic bile duct cancers. The
rate of liver cell cancer increased by around 45% in males, but by o10% in females. There were marked reductions in the incidence
of gallbladder and extrahepatic bile duct cancer. Cholangiocarcinoma increased around 16-fold and became the most common type
of primary liver cancer in females, while hepatocellular carcinoma remained the commonest type in males. The age-specific incidence
rates showed that intrahepatic bile duct cancer continued to increase throughout the 1990s in those aged 75 and over, while liver cell
cancer decreased in the older age groups. In conclusion, there were increases in the incidence of primary liver cancer, which have
been particularly dramatic for intrahepatic bile duct cancer, over the last three decades of the 20th century in England and Wales.
There has been a halving in the incidence of gallbladder cancer and a reduction of a third in extrahepatic bile duct cancer.
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Studies from the United States of America (USA) and the United
Kingdom (UK) have shown marked increases in mortality from
primary liver cancers in the last two decades of the 20th century
(Taylor-Robinson et al, 1997; El-Serag and Mason, 1999; Patel,
2001; Taylor-Robinson et al, 2001; Shaib et al, 2004). While there
have been incidence data reported from the USA, there has been
no report of recent trends (last 30 years) in incidence from the UK.
The data from the USA have shown that the incidence of, as well as
mortality from, both hepatocellular carcinoma and intrahepatic
cholangiocarcinoma has risen dramatically (El-Serag and Mason,
1999; Patel, 2001). The incidence rates of intra- and extrahepatic
cholangiocarcinoma in the USA, however, show divergent trends,
which may reflect changes in the classification of these malig-
nancies resulting from better diagnostic and histological techni-
ques. Nevertheless, it has been argued that the increase in the
incidence of intrahepatic cholangiocarcinoma is real, as there has
been no increase in the proportion of patients with either more
localised disease or a decrease in tumour size at diagnosis (Shaib
et al, 2004). However, reclassification of cases coded as carcinoma
not otherwise specified (NOS) or extrahepatic cholangiocarcino-
ma, which that study was unable to explore (Shaib et al, 2004),
could have contributed to the rise.
Since survival from cancers of the liver and gallbladder is quite
low, trends in mortality should be a reasonable proxy for trends in
incidence. However, a higher proportion of deaths than cases are
coded to ‘site unspecified’, indicating that diagnostic accuracy is
less certain for mortality than incidence. In addition, cancer
registrations include information about the histological classifica-
tion of tumours, which is not available from a death certificate. By
using incidence data and examining the trends in incidence by
subsite and histology, we will be able to more accurately describe
the trends in cancers of the liver and biliary tract, and to explore
whether there are any important differences between incidence
and mortality trends. We will also be able to see if the rise in
cholangiocarcinoma and reduction in extrahepatic biliary and
gallbladder cancers has continued into the 21st century.
MATERIALS AND METHODS
We used data collected in England by the nine regional cancer
registries, and in Wales by the Welsh Cancer Intelligence and
Surveillance Unit. A subset of the collected data for each patient
(the minimum data set) is sent to the National Cancer Intelligence
Centre at the Office for National Statistics (ONS). The data are
loaded onto a person-based database and validated (Office for
National Statistics, 2004). Validation includes checking the
compatibility of the cancer site and the associated histology.
We used validated registrations of cancers diagnosed from 1971
to 2001 for our analyses. The site codes of the International
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gallbladder and biliary tract cancer are shown in Table 1a.
International Classification of Disease (ICD8) (1967) was used for
cases diagnosed from 1971 to 1978, International Classification of
Disease (ICD9) (1975) from 1979 to 1994, and International
Classification of Disease (ICD10) (1992) from 1995 onwards. Cases
were excluded from the analysis if the behaviour of the tumour was
classified as benign, uncertain or in situ (o0.5% of the cases
registered from 1971 to 2001), leaving malignant primary tumours,
and a small number of malignant secondary tumours and tumours
not defined as primary or secondary (o4% of cases).
In addition to ICD site code, cases of cancer were classified by
histology code: those diagnosed from 1971 to 1978 using the
Manual of Tumor Nomenclature and Coding (MOTNAC) (1968),
those from 1979 to 1994 using the International Classification of
Disease for Oncology (ICD-O) (1976) and those from 1995
onwards using the second edition of this volume (International
Classification of Disease (ICD-O2), 1990). Cases were grouped
according to the following categories: neoplasm not otherwise
specified (NOS), code M800; carcinoma NOS, M801; adenocarci-
noma, M814; hepatocellular carcinoma, M817; cholangiocarcino-
ma, M816; and ‘other’ (all other codes) (see Table 1b). To assess
whether the proportion of registered cases that were diagnosed on
the basis of histological verification from a biopsy has changed
over time, we extracted data from 1993 to 2001. This information
was only routinely recorded on cancer registrations from 1993
onwards.
We calculated age-specific incidence rates for males and
females, and directly age-standardised rates were calculated by
weighting the age-specific rates according to the European
standard population. Rolling averages for 3 years were applied to
age-standardised rates, and 5-year rolling averages were applied to
age-specific rates, to smooth the trends over time. We calculated
rate ratios and 95% confidence intervals (CI) to compare the rates
between the 3-year periods at the beginning and end of the study
period.
All statistical analysis was carried out using Excel software.
Statistical significance was taken as Po0.05.
RESULTS
In 1999–2001, the overall age-standardised rate of cancers of the
liver, gallbladder and biliary tract was around 60% higher in males
than in females (6.13 and 3.89 per 100000 population, respectively;
Table 2 and Figure 1). By comparison, in 1971–73, the rate was
only about 30% higher in males (3.93 and 3.06 per 100000,
respectively). The incidence rates for cancers of the liver,
gallbladder and biliary tract increased by 56% (95% CI 46–66%)
in males and 27% (95% CI 18–37%) in females between 1971–73
and 1999–2001.
Incidence by subsite
In 1971–73, cancer of the intrahepatic bile ducts was rare in both
males and females (age-standardised rates 0.11 and 0.09 per
100000, respectively), but over the subsequent three decades the
incidence rates increased greatly, and were around 12 times higher
Table 1 ICD codes used to identify and group liver, gallbladder and biliary tract cancers
Definition ICD8 and 9 ICD10 Abbreviation
(a) Subsites
Liver, gallbladder and biliary tract 155, 156 C22–C24 TOTAL
Liver cell cancer 155.0 C22.0, C22.2–C22.7 LCC
Intrahepatic bile ducts 155.1 C22.1 IHBD
Liver unspecified 155.2 C22.9 LUS
Gallbladder 156.0 C23 GB
Extrahepatic bile ducts 156.1 C24.0 EHBD
Other parts of the biliary tract 156.2–156.9 C24.1–C24.9 OPBT
Definition ICD-O and ICD-O2 Abbreviation
(b) Histological types
Cholangiocarcinoma M816 CCA
Hepatocellular carcinoma M817 HCC
Adenocarcinoma M814 —
Carcinoma NOS M801 —
Neoplasm NOS+others M800 and all other codes not specified —
ICD, International Classification of Diseases; NOS, not otherwise specified.
Table 2 Incidence of cancers of the liver, gallbladder and biliary tract in England and Wales by subsite and sex per 100000 (using 3-year rolling averages
for the calculation of rates)
Males Females
Subsite 1971–73 1999–2001 Rate ratio 95% CI 1971–73 1999–2001 Rate ratio 95% CI
Liver, gallbladder and biliary tract (total) 3.93 6.13 1.56 1.46–1.66 3.06 3.89 1.27 1.18–1.37
Liver cell cancer 1.84 2.68 1.46 1.31–1.60 0.84 0.91 1.08 0.91–1.26
Intrahepatic bile ducts 0.11 1.33 12.19 10.92–13.46 0.09 1.06 11.94 10.68–13.20
Liver unspecified 0.27
a 0.58 2.15 1.74–2.56 0.13
a 0.28 2.07 1.58–2.57
Gallbladder 0.70 0.45 0.65 0.45–0.84 1.19 0.79 0.67 0.54–0.80
Extrahepatic bile ducts 0.86 0.42 0.48 0.32–0.65 0.67 0.36 0.53 0.37–0.69
Other parts of the biliary tract 0.42 0.68 1.61 1.31–1.91 0.27 0.50 1.85 1.50–2.20
CI, confidence interval.
a1979–1981.
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respectively; Table 2 and Figure 2). The rate of liver cell cancer
increased significantly by 46% (95% CI 31–60%) in males over the
period, from 1.84 to 2.68 per 100000, while in females there was
only a small, nonsignificant increase (from 0.84 to 0.91 per 100000;
8% increase 95% CI  9t oþ26%).
In both males and females, the rate of cancers of the liver
unspecified doubled and those of other parts of the biliary tree
increased by about 60–90% over the study period. There were
significant decreases in the rates of cancer of the gallbladder
(around 30%) and also of cancer of the extrahepatic bile ducts
(around 50%) between 1971–73 and 1999–2001 in both sexes.
In 1971–73, liver cell cancer was the most common subsite in
males and this remained the case in 1999–2001; the incidence rate
was around twice as high as that of cancer of the intrahepatic bile
ducts (2.68 and 1.33 per 100000, respectively). In females,
however, the rate of cancer of the intrahepatic bile ducts increased
by such a large amount over the study period that by 1999–2001
the rates of liver cell cancer and intrahepatic bile duct cancer were
similar (0.91 and 1.06 per 100000, respectively). In 1971–73, the
most common subsite in females was the gallbladder, but in 1999–
2001 intrahepatic bile duct was the most common, closely followed
by liver cell cancer.
It should be noted that, with the change for the coding of
cancers from ICD9 to ICD10 in 1995, which resulted in changes in
published rates (Rooney and Devis, 1996; Brock et al, 2004), there
were decreases in the rates of liver cell cancer (by just under 30%
between 1994 and 1995) and corresponding increases in the rates
of cancer of the intrahepatic bile ducts (by 60–70% between 1994
and 1995) in both sexes. In addition, the rates of cancers of the
liver unspecified increased (by about twofold between 1994 and
1995). These changes did not in general affect the underlying
trends in the rates of these types of cancer over the study period.
Age-specific incidence by subsite
The age-specific incidence rates in males for liver cell cancer and
cancer of the intrahepatic bile ducts are shown in Figure 3A and B,
respectively. The two figures show clear differences between the
two subsites, with a gradual increase in the rates of liver cell cancer
across the study period for all except the oldest age groups, where
the rates rose in the 1970s and fell in the 1990s. In contrast, the
rates of intrahepatic bile duct cancer increased quite slowly in all
age groups up to about 1990, and this was followed by a rapid
increase, which then levelled off in most of the age groups under 75
in the mid- to late 1990s.
The incidence of gallbladder and extrahepatic bile duct cancers
decreased markedly across all age groups from the late 1980s
onwards (Figure 3c and d, respectively). The trends in females
were similar (data not shown).
Incidence by histology
In 1971–73, the incidence rates of cholangiocarcinoma were very
low and were similar in males and females (0.08 and 0.07 per
100000, respectively). Incidence increased markedly and was
around 16 times higher at the end of the study period than at the
beginning in both males and females (1.35 and 1.13 per 100000,
respectively, in 1999–2001; Figure 4). Although it was the least
common histological type in 1971–73, cholangiocarcinoma was
the most common in females in 1999–2001, followed by
adenocarcinoma. The incidence of hepatocellular carcinoma was
around three times higher at the end of the study period than at
the beginning in both males and females, but was close to four
times higher in males than in females throughout. Hepatocellular
carcinoma was the least common histological type in females in
1999–2001 (13% of all cancers of the liver, gallbladder and biliary
tract), but in males it had become the most common type (34% of
all cancers of the liver, gallbladder and biliary tract).
The incidence rates of adenocarcinoma, carcinoma NOS and
neoplasm NOS and any other type not specified (neoplasm
NOSþother) were similar in males and females in 1971–73 and
followed similar trends across the following three decades. The
rates of adenocarcinoma in both sexes and neoplasm NOSþother
in females did not change significantly, while those of carcinoma
NOS decreased by 50% in females and 60% in males, and those of
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Figure 1 Trends in age-standardised incidence rates from 1971 to 2001 in England and Wales of all malignant cancers of the liver, gallbladder and biliary
tract, by sex (3-year rolling averages). Bars are standard errors.
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study period.
The proportion of cancers of the liver, gallbladder and biliary
tract that were diagnosed on the basis of histological verification
from a biopsy increased from 41% in 1993 to 48% in 2001. Of the
cases that were not histologically verified, the majority were
clinically diagnosed (58% on average in the period 1993–2001).
Histology by subsite
Between 1971 and 2001, there was a large increase in the
proportion of intrahepatic bile duct cancers coded as cholangio-
carcinoma, and corresponding decreases in the proportions coded
as adenocarcinoma and carcinoma NOS, indicating a move
towards more specific coding of histological types. A similar
pattern was observed for cancers of the extrahepatic bile ducts and
for liver cell cancers.
In 2001, hepatocellular carcinoma was used to classify only liver
cell cancers or cancers of the liver unspecified (with the exception
of a very small number of cases in other subsites). In all, o10% of
cancers of the liver unspecified were hepatocellular carcinomas,
with the majority classified as carcinoma NOS or neoplasm
NOSþother (Table 3). The proportion of liver cell cancers
classified as hepatocellular carcinoma differed between the sexes
– over 80% in males and just under 60% in females. This difference
was mainly due to a higher proportion being coded as carcinoma
NOS in females (19 vs 3% in males).
In both sexes, around 80% of intrahepatic bile duct cancers were
coded as cholangiocarcinoma, compared to around 30–40% of
extrahepatic bile duct cancers. For cancers of the liver unspecified,
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Figure 2 Trends in age-standardised incidence rates of all malignant cancers of the liver, gallbladder and biliary tract, by subsite from 1971 to 2001 in
England and Wales for (A) males and (B) females (3-year rolling averages). Liver cell cancer (LCC); cancer of the intrahepatic bile ducts (IHBD); cancer of
the liver, unspecified (LUS); cancer of the gallbladder (GB); cancer of the extrahepatic bile ducts (EHBD); and cancer of other parts of the biliary tract
(OPBT). For ICD site codes, see Table 1a.
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accounted for o10% of cases (Table 3).
DISCUSSION
In England and Wales, the incidence of cancers of the liver,
gallbladder and biliary tract increased over the last three decades
of the 20th century, particularly in males. The rates of intrahepatic
bile duct cancer increased dramatically in both sexes, whereas the
rate of liver cell cancer increased significantly in males, but not in
females. In 1999–2001, liver cell cancer was the most common
subsite in males and was twice as common as intrahepatic bile duct
cancer. In contrast, intrahepatic bile duct cancer was the most
common subsite in females. These incidence trends show some
divergence from the previously reported mortality statistics. In
addition, there were dramatic reductions in the incidence of
extrahepatic bile duct and gallbladder cancers in both men and
women.
In terms of histological type, the trends were quite similar
between the sexes. The incidence of cholangiocarcinoma increased
by around 16-fold, and that of hepatocellular carcinoma by
threefold over the last three decades of the 20th century. These
increases were too large to be accounted for by a shift in coding
from other histological types over the period. Our examination of
the agreement between subsite and histological type showed that
over 80% of cholangiocarcinomas were intrahepatic (coded as
intrahepatic bile duct cancer) and around 95% of hepatocellular
carcinomas were coded as liver cell cancer.
Our use of cancer incidence data has provided the opportunity
to examine long-term incidence trends for these cancers in
England and Wales, where only mortality data have recently been
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Figure 3 Trends in age-specific incidence rates in males from 1971 to 2001 in England and Wales of (A) liver cell cancer, (B) cancer of the intrahepatic
bile ducts, (C) cancer of the gallbladder and (D) cancer of the extrahepatic bile ducts (3-year rolling averages).
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proportion diagnosed on the basis of histology and our age-
specific analyses have allowed greater examination of the
possibility of ascertainment bias than is possible with mortality
statistics. As might be expected, the trends in incidence are similar
to those reported for mortality in England and Wales. Indeed, the
mortality trends in both liver cell cancer and intrahepatic bile duct
cancer for both men and women up until 1996 showed, as we do,
that in women intrahepatic bile duct cancer was the most common
type, in contrast to men, in whom liver cell cancer was most
common. It might be argued that the increase we show in
intrahepatic bile duct cancer reflects greater ascertainment
consequent upon improved endoscopic and radiological techni-
ques. Indeed, this interpretation has some support, since we found
that the proportion of all liver, gallbladder and biliary tract cancers
that were diagnosed on the basis of histological verification from a
biopsy increased between 1993 and 2001. It is also possible that
some of the increase in intrahepatic bile duct cancer may be due to
diagnostic transfer from cases that were previously coded as
extrahepatic bile duct cancer, although the reductions in extra-
hepatic bile duct cancer over the period were small.
Imaging modalities such as computerised tomography (CT) and
endoscopic retrograde cholangiopancreatography (ERCP) have
been available in most UK hospitals since the mid-1980s (McCune,
1988; Scott and Atkinson, 1989), but the increase in the incidence
of intrahepatic bile duct cancer has continued at the same rate
even in the last decade. Therefore, while some of the rise might be
explained by increased ascertainment (i.e. increased use of
imaging modalities over time in line with the increasing
incidence), and certainly the increase in the proportion of cases
diagnosed on the basis of histology suggests that this is partly
responsible, we believe that this is not sufficient explanation. In
particular, our analysis by histological type showed that the
increase in the incidence of cholangiocarcinoma was far greater
than the decreases in carcinoma NOS and neoplasm NOSþother.
The marked decrease in gallbladder cancer is also unlikely to be
anything other than a true trend, as ascertainment is unlikely to be
an issue for this particular malignancy. Furthermore, diagnostic
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yTable 3 Subsite by histology: percent of all cases of cancers of the liver, gallbladder and biliary tract in England and Wales within subsite by sex, 2001
Males Females
Subsite N (100%) CCA HCC Adeno Carc NOS+other N (100%) CCA HCC Adeno Carc NOS+other
Liver cell cancer 747 0.4 83.7 3.7 2.9 9.2 380 1.3 58.9 9.7 19.7 10.3
Intrahepatic biliary ducts 430 78.8 0.2 2.8 3.5 14.7 455 83.5 0.2 1.5 5.3 9.5
Liver unspecified 143 3.5 9.1 8.4 43.4 35.7 118 5.9 7.6 8.5 38.1 39.8
Gallbladder 146 8.2 0.0 47.3 26.0 18.5 319 4.1 0.3 45.1 33.5 16.9
Extrahepatic bile ducts 108 38.0 0.9 22.2 20.4 18.5 137 30.7 0.7 20.4 24.8 23.4
Other parts of the biliary tract 203 7.4 0.0 57.6 18.2 16.7 197 8.6 0.0 55.8 24.4 11.2
N, number of cases; CCA, cholangiocarcinoma; HCC, hepatocellular carcinoma; adeno, adenocarcinoma; carc, carcinoma not otherwise specified; NOS+other, neoplasms not
otherwise specified, and all other codes.
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Figure 4 Trends in age-standardised incidence rates of all malignant cancers of the liver, gallbladder and biliary tract by histological type from 1971 to
2001 in England and Wales for (A) males and (B) females (3-year rolling averages). For histology codes, see Table 1b.
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whelmingly in intrahepatic cholangiocarcinoma or why there are
the differences in the age-specific patterns seen in Figure 3.
The reasons behind the increasing incidence of intrahepatic
cholangiocarcinoma are unclear. Two recent studies from the USA
suggested that the same risk factors could predispose to both the
main forms of primary liver cancer (Davila et al, 2005; Shaib et al,
2005). Shaib et al (2005) found hepatitis C infection, alcoholic liver
disease and liver cirrhosis, well-established risk factors for
hepatocellular cancer, to be strongly associated with intrahepatic
cholangiocarcinoma. Intriguingly, using a similar study design,
they found comparable associations for the same risk factors and
hepatocellular carcinoma (Davila et al, 2005). Our findings would,
however, suggest that these cancers do not necessarily have similar
risk factors.
In conclusion, we have found increases in the incidence of
primary liver cancer, which have been particularly dramatic for
intrahepatic bile duct cancer, over the last three decades of the
20th century in England and Wales. There has been a halving in
the incidence of gallbladder cancer and a reduction of a third in
extrahepatic bile duct cancer. Cholangiocarcinoma became the
commonest type of primary liver cancer in females in contrast to
males, in whom hepatocellular carcinoma remains the most
common. The trends in the incidence of intrahepatic bile duct
cancer and liver cell cancer follow strikingly different patterns,
overall and in the older age groups, suggesting that the two main
types of primary liver cancer are unlikely to completely share
common aetiologies.
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